Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test could make allergy diagnosis faster and easier

NCT ID NCT07596303

Diagnosis Sponsor: Bühlmann Laboratories AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study is testing a new blood test (called BÜHLMANN BAT) to see if it can help diagnose allergies to peanuts, insect venom, dust mites, hazelnut, and cat dander. About 60 people aged 1.5 years and older who are already being checked for allergies will give one extra tube of blood during their regular visit. The test is not yet proven, and participants will not get direct personal benefits from joining.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

38 people

The number who actually took part.

Started

May 2026

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be invited during a routine diagnostic visit to the Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein to contribute to the study by giving one additional sample tube. This extra sample will be collected alongside the venous blood samples already being taken as part of their standard care.

Ages

18 months and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals with diagnosis of a hypersensitivity / allergy to one of the 6 allergens, established according to common clinical practice Exclusion Criteria: * Pregnant women * Children under the age of 18 months * Individuals under therapy with Omalizumab or Rituximab * Individuals with an allergic reaction less than two weeks before blood sample collection * Individuals under therapy with BTK inhibitors * Individuals receiving allergen specific immunotherapy (ASIT) * Subjects with active infection and inflammatory conditions * Patients who are unable to understand the study information and informed consent form in German

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergy testing are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic rhinitis atopy, domestic cat Dust Mite Allergy food allergy Peanut Hypersensitivity venom allergy Venom Hypersensitivity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergy testing Cat epithelium allergy Hazelnut allergy House dust mite allergy Peanut allergies Venom allergy

Contacts and locations

Locations

  • Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, TUM Universitätsklinikum rechts der Isar,

    München, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.